Takeda Pharmaceutical Company Limited (TAK)
NYSE: TAK · Real-Time Price · USD
14.32
+0.01 (0.07%)
At close: Jul 29, 2025, 4:00 PM
14.32
0.00 (0.00%)
After-hours: Jul 29, 2025, 4:56 PM EDT
Takeda Pharmaceutical Employees
Takeda Pharmaceutical Company had 47,455 employees as of March 31, 2025. The number of employees decreased by 1,826 or -3.71% compared to the previous year.
Employees
47,455
Change (1Y)
-1,826
Growth (1Y)
-3.71%
Revenue / Employee
$644,718
Profits / Employee
$15,188
Market Cap
45.11B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Mar 31, 2025 | 47,455 | -1,826 | -3.71% |
Mar 31, 2024 | 49,281 | 186 | 0.38% |
Mar 31, 2023 | 49,095 | 1,748 | 3.69% |
Mar 31, 2022 | 47,347 | 248 | 0.53% |
Mar 31, 2021 | 47,099 | -396 | -0.83% |
Mar 31, 2020 | 47,495 | -2,083 | -4.20% |
Mar 31, 2019 | 49,578 | 22,348 | 82.07% |
Mar 31, 2018 | 27,230 | -2,670 | -8.93% |
Mar 31, 2017 | 29,900 | -1,268 | -4.07% |
Mar 31, 2016 | 31,168 | -160 | -0.51% |
Mar 31, 2015 | 31,328 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 94,300 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
TAK News
- 8 days ago - Takeda Receives FDA 510(k) Clearance for HyHubTM and HyHubTM Duo Devices to Simplify HYQVIA® Administration - Business Wire
- 12 days ago - Takeda: Positioned To Tackle Future Clinical Demand In A Highly Regulated Sector - Seeking Alpha
- 15 days ago - Takeda Announces Positive Results from Two Pivotal Phase 3 Studies of Oveporexton (TAK-861) in Narcolepsy Type 1 - Business Wire
- 4 weeks ago - Takeda Announces U.S. FDA Approval of GAMMAGARD LIQUID ERC, the Only Ready-to-Use Liquid Immunoglobulin Therapy with Low Immunoglobulin A (IgA) Content1 - Business Wire
- 4 weeks ago - Takeda Announces New Assignments of Directors - Business Wire
- 2 months ago - European Commission Approves ADCETRIS® (brentuximab vedotin) for the Treatment of Adult Patients with Newly Diagnosed Stage IIb/III/IV Hodgkin Lymphoma in Combination with ECADD - Business Wire
- 2 months ago - Protagonist and Takeda Announce ASCO Plenary Presentation Highlighting Full 32-Week Results from Phase 3 VERIFY Study of Rusfertide, Showing Reductions in Phlebotomy, Improved Hematocrit Control in Polycythemia Vera - Business Wire
- 2 months ago - Takeda and Nature Announce Call for Applications Now Open for 2026 Innovators in Science Award - Business Wire